Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Matrix metalloproteinase-1 treatment of muscle fibrosis

Kaar, JL and Li, Y and Blair, HC and Asche, G and Koepsel, RR and Huard, J and Russell, AJ (2008) Matrix metalloproteinase-1 treatment of muscle fibrosis. Acta Biomaterialia, 4 (5). 1411 - 1420. ISSN 1742-7061

[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)


The onset of scarring after injury may impede the regeneration and functional recovery of skeletal muscle. Matrix metalloproteinase-1 (MMP-1) hydrolyzes type I collagen and thus may improve muscle regeneration by resolving fibrotic tissue. We examined the effect of recombinant human MMP-1 on fibrosis in the lacerated gastrocnemius muscle of NOD/scid mice, allowing treatment potential to be ascertained in isolation from immune response. The efficacy of proMMP-1 and active MMP-1 were compared with or without poly(ethylene glycol) (PEG) modification, which was intended to increase the enzyme's stability. Active MMP-1 was most effective in reducing fibrosis, although treatment with proMMP-1 was also beneficial relative to controls. PEG-modified MMP-1 had minimal activity in vivo, despite retaining activity towards a thioester substrate. Moreover, the modified enzyme was inactivated by trypsin and subtilisin at rates comparable to that of native MMP-1. These results and those of computational structural studies suggest that modification occurs at the C-terminal hemopexin domain of MMP-1, which plays a critical role in collagen turnover. Site-specific modifications that spares catalytic and substrate binding sites while protecting susceptible proteolytic digestion sites may be beneficial. We conclude that active MMP-1 can effectively reduce muscle scarring and that its activity is related to the ability of the enzyme to digest collagen, thereby facilitating remodeling of the injured muscle. © 2008 Acta Materialia Inc.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Kaar, JL
Li, Y
Blair, HC
Asche, G
Koepsel, RR
Huard, J
Russell, AJ
Centers: Other Centers, Institutes, Offices, or Units > McGowan Institute for Regenerative Medicine
Date: 1 January 2008
Date Type: Publication
Journal or Publication Title: Acta Biomaterialia
Volume: 4
Number: 5
Page Range: 1411 - 1420
DOI or Unique Handle: 10.1016/j.actbio.2008.03.010
Schools and Programs: School of Medicine > Orthopaedic Surgery
School of Medicine > Pathology
School of Medicine > Surgery
Swanson School of Engineering > Chemical Engineering
Swanson School of Engineering > Petroleum Engineering
Refereed: Yes
ISSN: 1742-7061
MeSH Headings: Animals; Fibrosis--drug therapy; Fibrosis--pathology; Humans; Matrix Metalloproteinase 1--administration & dosage; Matrix Metalloproteinase 1--genetics; Mice; Mice, SCID; Muscle, Skeletal--drug effects; Muscle, Skeletal--pathology; Recombinant Proteins--therapeutic use; Treatment Outcome
PubMed ID: 18440885
Date Deposited: 15 May 2014 20:34
Last Modified: 24 Dec 2021 23:55


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item